epiClinicalA fictional CRO

epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.

EPI-620, Phase III. In planning

Chronic obstructive pulmonary disease with frequent exacerbations

LWR-620 against placebo to reduce exacerbations in COPD. Sponsor: Litware Respiratory (fictional), Respiratory.

When will this study finish recruiting? Set its sites yourself, or let the planner find the fewest per country that meet the deadline.

Study and plan

Litware Respiratory (fictional), Phase III, Respiratory. Month 0 is January 2027.
Randomise 706 (drop-out 15%) and screen about 1177 (screen failure 40%)
Jul 2029
Confidence wanted
Sites per country
The fewest sites that finish by the deadline with the confidence above, within each country's cap
How much sites differ
Spread of site rates (coefficient of variation 0.9). Fitted trials range from 0.7 to 1.2.
  • Central finish (P50)Feb 2029month 25.8
  • Fast case (P10)Nov 2028month 22.3
  • Slow case (P90)Jul 2029month 31.0
  • Chance of meeting the deadline86%wanted 85%
  • Sites20720% likely to recruit nobody
  • Patients to screen1,177to randomise 706

On course to finish in February 2029, four months before the deadline

EPI-620, patients randomised, cumulative by monthThe band holds 80% of 4,000 simulated studies; the coloured line is the central forecast

Show data
Patients randomised by month: fast, central and slow cases of the simulation, and actual recruitment
MonthFast caseCentralSlow case
Jan 2027000
Apr 2027000
Jul 2027731
Oct 2027433019
Jan 202813410073
Apr 2028278212157
Jul 2028450346257
Oct 2028630483360
Jan 2029706622464
Apr 2029706706567
Jul 2029706706673
Oct 2029706706706
Jan 2030706706706
Apr 2030706706706
Jul 2030706706706

Source: epiClinical Poisson-gamma simulation. All data synthetic.

How likely is it to finish by a given month?

About a four-in-five chance of finishing by July 2029

Finish month of 4,000 simulated studiesOne dot = 40 simulated studies · 86 of 100 dots finish in time

Drag the handle or
In time: 86%Median Feb 2029Late: 14%

Source: epiClinical Poisson-gamma simulation

Show data
Chance that recruitment is complete by the end of each month
MonthChance complete by then
Jan 20270%
Apr 20270%
Jul 20270%
Oct 20270%
Jan 20280%
Apr 20280%
Jul 20280%
Oct 20283%
Jan 202927%
Apr 202963%
Jul 202986%
Oct 202996%
Jan 203099%
Apr 2030100%
Jul 2030100%

Countries

UseCountryPatients per site per monthSites open betweenCapSitesPatients by finish
United States
0.163
  • Therapeutic area: 0.400 Respiratory baseline
  • Country: ×0.75 United States
  • Site type: ×0.988 Usual mix in United States
  • Track record: ×0.98 Expected mix for mostly repeat sites
  • Protocol and population: ×0.8 Moderately restrictive eligibility ×0.8
  • Patient acceptability: ×0.7 Placebo or no added treatment ×0.75, Blinded ×0.8, Yes ×1.1
  • Competing trials: ×1 A few ×1
month 4.1 to 10.2 1001854
United Kingdom
0.182
  • Therapeutic area: 0.400 Respiratory baseline
  • Country: ×0.85 United Kingdom
  • Site type: ×0.975 Usual mix in United Kingdom
  • Track record: ×0.98 Expected mix for mostly repeat sites
  • Protocol and population: ×0.8 Moderately restrictive eligibility ×0.8
  • Patient acceptability: ×0.7 Placebo or no added treatment ×0.75, Blinded ×0.8, Yes ×1.1
  • Competing trials: ×1 A few ×1
month 4.0 to 10.0 4444150
Spain
0.215
  • Therapeutic area: 0.400 Respiratory baseline
  • Country: ×1 Spain
  • Site type: ×0.977 Usual mix in Spain
  • Track record: ×0.98 Expected mix for mostly repeat sites
  • Protocol and population: ×0.8 Moderately restrictive eligibility ×0.8
  • Patient acceptability: ×0.7 Placebo or no added treatment ×0.75, Blinded ×0.8, Yes ×1.1
  • Competing trials: ×1 A few ×1
month 7.6 to 13.6 7171230
Poland
0.316
  • Therapeutic area: 0.400 Respiratory baseline
  • Country: ×1.4 Poland
  • Site type: ×1.028 Usual mix in Poland
  • Track record: ×0.98 Expected mix for mostly repeat sites
  • Protocol and population: ×0.8 Moderately restrictive eligibility ×0.8
  • Patient acceptability: ×0.7 Placebo or no added treatment ×0.75, Blinded ×0.8, Yes ×1.1
  • Competing trials: ×1 A few ×1
month 11.1 to 17.1 4141150
Turkey
0.212
  • Therapeutic area: 0.400 Respiratory baseline
  • Country: ×1 Turkey
  • Site type: ×0.965 Usual mix in Turkey
  • Track record: ×0.98 Expected mix for mostly repeat sites
  • Protocol and population: ×0.8 Moderately restrictive eligibility ×0.8
  • Patient acceptability: ×0.7 Placebo or no added treatment ×0.75, Blinded ×0.8, Yes ×1.1
  • Competing trials: ×1 A few ×1
month 6.0 to 12.0 181864
India
0.230
  • Therapeutic area: 0.400 Respiratory baseline
  • Country: ×1.1 India
  • Site type: ×0.952 Usual mix in India
  • Track record: ×0.98 Expected mix for mostly repeat sites
  • Protocol and population: ×0.8 Moderately restrictive eligibility ×0.8
  • Patient acceptability: ×0.7 Placebo or no added treatment ×0.75, Blinded ×0.8, Yes ×1.1
  • Competing trials: ×1 A few ×1
month 6.0 to 12.0 151558

Country risks to weigh when choosing sites

United States

Two sourced risks

  • All sites

    The first US site opens quickly, but the rest of the US sites open slowly.

    The US activates its first site quickly but scales its site fleet slowly · PM-03 · grade B

    Tightens: site activation overdue

  • All sites

    Under-represented groups need a plan from the start; diversity action plans apply to Phase III studies.

    Racial and ethnic under-representation · PB-12 · grade A

United Kingdom

Two sourced risks

  • Some sites

    Costing and contracting were the longest start-up step; the national contract has shortened it.

    Fragmented, negotiated costing and contracting · POL-03 · grade A

  • If it recurs

    The regulator's backlog of 2023 was cleared, but could recur.

    Regulator assessment backlog · POL-02 · grade A

Spain

Two sourced risks

  • All sites

    Site contracts took 117 days in 2016 and about 90 after national templates.

    Fragmented, negotiated costing and contracting · POL-03 · grade A

  • All sites

    Applications go through the EU Clinical Trials Regulation and its portal.

    Regional regulatory transition friction (EU CTR and CTIS) · POL-15 · grade A

Poland

Two sourced risks

  • All sites

    Applications go through the EU Clinical Trials Regulation and its portal.

    Regional regulatory transition friction (EU CTR and CTIS) · POL-15 · grade A

  • All sites

    A central ethics committee reviews every study; its effect on timelines is not measured.

    Ethics-committee structure (random CPP allocation, 40 Italian territorial committees, a central Polish committee, Denmark's timeliness) · POL-20 · grade B

Turkey

Four sourced risks

  • All sites

    Ethics committees fell from 145 to 49 in 2024, cutting review capacity.

    Ethics-committee re-registration or re-constitution that cuts review capacity (India 2013; Turkey 2024) · RW-05 · grade B

    Tightens: site activation overdue

  • All sites

    A fixed pharmaceutical exchange rate has caused repeated medicine shortages.

    Currency crisis with a fixed pharmaceutical exchange rate (Turkey 2018–2026) · RW-07 · grade D

    Tightens: study drug at the site

  • All sites

    Start-up time has not been measured since CRO data from 2014 and 2015.

    Start-up time for India and Turkey is unmeasured · PM-04 · grade C

  • If it recurs

    Sites in the south-east lie in the 2023 earthquake zone.

    Major earthquake in a site region · SH-11 · grade C

India

Two sourced risks

  • All sites

    Vulnerable participants in trials of new drugs need an audio-visual record of their consent.

    Mandatory audio-visual consent for all participants · RW-03 · grade C

    Tightens: consent findings

  • All sites

    Start-up time is unmeasured beyond the statutory 90 working days.

    Start-up time for India and Turkey is unmeasured · PM-04 · grade C

    Tightens: site activation overdue

Risk-register entries; the choice of entries per country is epiClinical's.